

Jan Schwab

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/853853/publications.pdf>

Version: 2024-02-01

98
papers

7,343
citations

70961

41
h-index

56606

83
g-index

101
all docs

101
docs citations

101
times ranked

9063
citing authors

#	ARTICLE	IF	CITATIONS
1	Dynamic induction of the myelin-associated growth inhibitor NogoA in perilesional plasticity regions after human spinal cord injury. <i>Brain Pathology</i> , 2023, 33, .	2.1	2
2	Acute Spinal Cord Injury Is Associated With Prevalent Cardiometabolic Risk Factors. <i>Archives of Physical Medicine and Rehabilitation</i> , 2022, 103, 696-701.	0.5	19
3	The Effect of Early Infection on the Rate of Volitional Voiding after Spinal Cord Injury: A Potential Modifiable Risk Factor for Bladder Outcomes. <i>Journal of Urology</i> , 2022, 207, 137-143.	0.2	5
4	Association of age with the timing of acute spine surgery—effects on neurological outcome after traumatic spinal cord injury. <i>European Spine Journal</i> , 2022, 31, 56-69.	1.0	6
5	A critical reappraisal of corticospinal tract somatotopy and its role in traumatic cervical spinal cord syndromes. <i>Journal of Neurosurgery: Spine</i> , 2022, 36, 653-659.	0.9	5
6	Bladder Management With Chronic Indwelling Catheter is Associated with Elevated Mortality in Patients with Spinal Cord Injury. <i>Urology</i> , 2022, , .	0.5	5
7	Thoracic VGlut2 ⁺ Spinal Interneurons Regulate Structural and Functional Plasticity of Sympathetic Networks after High-Level Spinal Cord Injury. <i>Journal of Neuroscience</i> , 2022, 42, 3659-3675.	1.7	9
8	Immune dysfunction after spinal cord injury — A review of autonomic and neuroendocrine mechanisms. <i>Current Opinion in Pharmacology</i> , 2022, 64, 102230.	1.7	13
9	Spinal Cord Injury Impairs Lung Immunity in Mice. <i>Journal of Immunology</i> , 2022, 209, 157-170.	0.4	4
10	Acute and non-resolving inflammation associate with oxidative injury after human spinal cord injury. <i>Brain</i> , 2021, 144, 144-161.	3.7	95
11	The neuroanatomical—functional paradox in spinal cord injury. <i>Nature Reviews Neurology</i> , 2021, 17, 53-62.	4.9	82
12	Serum albumin as a predictor of neurological recovery after spinal cord injury: a replication study. <i>Spinal Cord</i> , 2021, 59, 282-290.	0.9	10
13	Prognostic value of early leukocyte fluctuations for recovery from traumatic spinal cord injury. <i>Clinical and Translational Medicine</i> , 2021, 11, e272.	1.7	30
14	Profiling age-related muscle weakness and wasting: neuromuscular junction transmission as a driver of age-related physical decline. <i>GeroScience</i> , 2021, 43, 1265-1281.	2.1	24
15	Peripheral white blood cell responses as emerging biomarkers for patient stratification and prognosis in acute spinal cord injury. <i>Current Opinion in Neurology</i> , 2021, 34, 796-803.	1.8	11
16	FAIR SCI Ahead: The Evolution of the Open Data Commons for Pre-Clinical Spinal Cord Injury Research. <i>Journal of Neurotrauma</i> , 2020, 37, 831-838.	1.7	27
17	Enhanced axonal response of mitochondria to demyelination offers neuroprotection: implications for multiple sclerosis. <i>Acta Neuropathologica</i> , 2020, 140, 143-167.	3.9	48
18	Clinical decision-making on spinal cord injury-associated pneumonia: a nationwide survey in Germany. <i>Spinal Cord</i> , 2020, 58, 873-881.	0.9	10

#	ARTICLE	IF	CITATIONS
19	Association of timing of gabapentinoid use with motor recovery after spinal cord injury. <i>Neurology</i> , 2020, 95, e3412-e3419.	1.5	4
20	Neurochemical biomarkers in spinal cord injury. <i>Spinal Cord</i> , 2019, 57, 819-831.	0.9	65
21	The Incidence and Management of Moderate to Severe Head Injury. <i>Deutsches A&#x0308;rztblatt International</i> , 2019, 116, 167-173.	0.6	51
22	Outcome heterogeneity and bias in acute experimental spinal cord injury. <i>Neurology</i> , 2019, 93, e40-e51.	1.5	24
23	Overcoming trivialization: The neuroimmune response after acute central nervous system injury. <i>Journal of Neuroimmunology</i> , 2019, 330, 28-30.	1.1	0
24	SCINGâ€™ Spinal Cord Injury Neuroprotection with Glyburide: a pilot, open-label, multicentre, prospective evaluation of oral glyburide in patients with acute traumatic spinal cord injury in the USA. <i>BMJ Open</i> , 2019, 9, e031329.	0.8	14
25	Assessing Rat Forelimb and Hindlimb Motor Unit Connectivity as Objective and Robust Biomarkers of Spinal Motor Neuron Function. <i>Scientific Reports</i> , 2019, 9, 16699.	1.6	8
26	Markedly Deranged Injury Site Metabolism and Impaired Functional Recovery in Acute Spinal Cord Injury Patients With Fever. <i>Critical Care Medicine</i> , 2018, 46, 1150-1157.	0.4	17
27	Impact of Admission Imaging Findings on Neurological Outcomes in Acute Cervical Traumatic Spinal Cord Injury. <i>Journal of Neurotrauma</i> , 2018, 35, 1398-1406.	1.7	48
28	Serum Albumin Predicts Long-Term Neurological Outcomes After Acute Spinal Cord Injury. <i>Neurorehabilitation and Neural Repair</i> , 2018, 32, 7-17.	1.4	28
29	Considerations and recommendations for selection and utilization of upper extremity clinical outcome assessments in human spinal cord injury trials. <i>Spinal Cord</i> , 2018, 56, 414-425.	0.9	24
30	Lower extremity outcome measures: considerations for clinical trials in spinal cord injury. <i>Spinal Cord</i> , 2018, 56, 628-642.	0.9	23
31	Determinants of Axon Growth, Plasticity, and Regeneration in the Context of Spinal Cord Injury. <i>American Journal of Pathology</i> , 2018, 188, 53-62.	1.9	45
32	Corroborating evidence by exploring sources of bias in observational spinal cord injury studies. <i>Neurology</i> , 2018, 91, 476-479.	1.5	2
33	American Academy of Spinal Cord Injury Professionals ASCIP 2018 Educational Conference & Expo Stronger Together: Passion, Purpose and Possibilities in SCI/D. <i>Journal of Spinal Cord Medicine</i> , 2018, 41, 599-622.	0.7	0
34	Raising awareness for spinal cord injury research. <i>Lancet Neurology</i> , The, 2018, 17, 581-582.	4.9	17
35	Long-term functional outcome in patients with acquired infections after acute spinal cord injury. <i>Neurology</i> , 2017, 88, 892-900.	1.5	87
36	Challenges to Translation and the Hippocratic Oath by Premature Termination of Spinal Cord Stem Cellâ€™Based Trials. <i>JAMA Neurology</i> , 2017, 74, 635.	4.5	11

#	ARTICLE	IF	CITATIONS
37	Spinal cord injury-induced immunodeficiency is mediated by a sympathetic-neuroendocrine adrenal reflex. <i>Nature Neuroscience</i> , 2017, 20, 1549-1559.	7.1	133
38	Maresin 1 Promotes Inflammatory Resolution, Neuroprotection, and Functional Neurological Recovery After Spinal Cord Injury. <i>Journal of Neuroscience</i> , 2017, 37, 11731-11743.	1.7	130
39	Developing a data sharing community for spinal cord injury research. <i>Experimental Neurology</i> , 2017, 295, 135-143.	2.0	48
40	Modifiable denominators of evolving post-stroke-autoimmunity. <i>Journal of Neuroimmunology</i> , 2016, 300, 57-58.	1.1	0
41	SCISSOR – Spinal Cord Injury Study on Small molecule-derived Rho inhibition: a clinical study protocol. <i>BMJ Open</i> , 2016, 6, e010651.	0.8	17
42	Natural Killer (NK) Cell Functionality after human Spinal Cord Injury (SCI): protocol of a prospective, longitudinal study. <i>BMC Neurology</i> , 2016, 16, 170.	0.8	23
43	Neuroprotection After Traumatic Brain Injury. <i>JAMA Neurology</i> , 2016, 73, 149.	4.5	8
44	Spinal cord injury-induced immune deficiency syndrome enhances infection susceptibility dependent on lesion level. <i>Brain</i> , 2016, 139, 692-707.	3.7	180
45	Olfactory Ensheathing Cell Transplantation in Experimental Spinal Cord Injury: Effect size and Reporting Bias of 62 Experimental Treatments: A Systematic Review and Meta-Analysis. <i>PLoS Biology</i> , 2016, 14, e1002468.	2.6	70
46	Anti-Inflammatory Effects of IL-27 in Zymosan-Induced Peritonitis: Inhibition of Neutrophil Recruitment Partially Explained by Impaired Mobilization from Bone Marrow and Reduced Chemokine Levels. <i>PLoS ONE</i> , 2015, 10, e0137651.	1.1	24
47	Large animal and primate models of spinal cord injury for the testing of novel therapies. <i>Experimental Neurology</i> , 2015, 269, 154-168.	2.0	75
48	Timed Action of IL-27 Protects from Immunopathology while Preserving Defense in Influenza. <i>PLoS Pathogens</i> , 2014, 10, e1004110.	2.1	62
49	Enabling motor control in chronic spinal cord injury: found in translation. <i>Brain</i> , 2014, 137, 1277-1280.	3.7	2
50	Effect and Reporting Bias of RhoA/ROCK-Blockade Intervention on Locomotor Recovery After Spinal Cord Injury. <i>JAMA Neurology</i> , 2014, 71, 91.	4.5	80
51	The paradox of chronic neuroinflammation, systemic immune suppression, autoimmunity after traumatic chronic spinal cord injury. <i>Experimental Neurology</i> , 2014, 258, 121-129.	2.0	204
52	The SCIentinel study - prospective multicenter study to define the spinal cord injury-induced immune depression syndrome (SCI-IDS) - study protocol and interim feasibility data. <i>BMC Neurology</i> , 2013, 13, 168.	0.8	41
53	Current Practice of Methylprednisolone Administration for Acute Spinal Cord Injury in Germany. <i>Spine</i> , 2013, 38, E669-E677.	1.0	28
54	Proresolutive Lipid Mediators in Multiple Sclerosis – Differential, Disease Severity-Dependent Synthesis – A Clinical Pilot Trial. <i>PLoS ONE</i> , 2013, 8, e55859.	1.1	85

#	ARTICLE	IF	CITATIONS
55	Evidence of Intrathecal Immunoglobulin Synthesis in Stroke. Archives of Neurology, 2012, 69, 714-7.	4.9	40
56	Functional neurological recovery after spinal cord injury is impaired in patients with infections. Brain, 2012, 135, 3238-3250.	3.7	132
57	N-ethyl-L-aspartate receptor antibodies in herpes simplex encephalitis. Annals of Neurology, 2012, 72, 902-911.	2.8	343
58	Querschnittslähmung muss heilbar werden – das ambitionierte Ziel der Wings for Life Stiftung. Sports Orthopaedics and Traumatology, 2012, 28, 66-73.	0.1	0
59	Repulsive guidance molecule-A (RGM-A) inhibits leukocyte migration and mitigates inflammation. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 6555-6560.	3.3	55
60	Non-Resolving Aspects of Acute Inflammation after Spinal Cord Injury (SCI): Indices and Resolution Plateau. Brain Pathology, 2011, 21, 652-660.	2.1	93
61	Spinal cord injury induces differential expression of the profibrotic semaphorin 7A in the developing and mature glial scar. Glia, 2010, 58, 1748-1756.	2.5	30
62	Sekundäre Immundefizienz (Immunparalyse) nach Rückenmarkverletzung. E-Neuroforum, 2010, 16, 208-217.	0.2	0
63	Lumbar spinal stenosis: syndrome, diagnostics and treatment. Nature Reviews Neurology, 2009, 5, 392-403.	4.9	147
64	Hypoxia-inducible factor-dependent induction of netrin-1 dampens inflammation caused by hypoxia. Nature Immunology, 2009, 10, 195-202.	7.0	369
65	Anesthetics Impact the Resolution of Inflammation. PLoS ONE, 2008, 3, e1879.	1.1	101
66	Spinal cord injury-induced expression of the antiangiogenic endostatin/collagen XVIII in areas of vascular remodelling. Journal of Neurosurgery: Spine, 2007, 7, 205-214.	0.9	6
67	Resolvin E1 and protectin D1 activate inflammation-resolution programmes. Nature, 2007, 447, 869-874.	13.7	1,046
68	Spinal cord injury-induced immune depression syndrome (SCI-IDS). European Journal of Neuroscience, 2007, 25, 1743-1747.	1.2	121
69	Expression of interleukin-16 by tumor-associated macrophages/activated microglia in high-grade astrocytic brain tumors. Archivum Immunologiae Et Therapiae Experimentalis, 2007, 55, 41-47.	1.0	39
70	Lipoxins and new lipid mediators in the resolution of inflammation. Current Opinion in Pharmacology, 2006, 6, 414-420.	1.7	180
71	Experimental strategies to promote spinal cord regeneration – an integrative perspective. Progress in Neurobiology, 2006, 78, 91-116.	2.8	197
72	Spinal cord injury-induced expression of the immune-regulatory chemokine interleukin-16 caused by activated microglia/macrophages and CD8+ cells. Journal of Neurosurgery: Spine, 2006, 4, 233-240.	0.9	36

#	ARTICLE	IF	CITATIONS
73	Central Nervous System Injuryâ€œInduced Repulsive Guidance Molecule Expression in the Adult Human Brain. Archives of Neurology, 2005, 62, 1561-8.	4.9	75
74	Central nervous system injury-induced immune deficiency syndrome. Nature Reviews Neuroscience, 2005, 6, 775-786.	4.9	776
75	Spinal cord injuryâ€œinduced lesional expression of the repulsive guidance molecule (RGM). European Journal of Neuroscience, 2005, 21, 1569-1576.	1.2	104
76	Spinal cord injury induces early and persistent lesional P2X4 receptor expression. Journal of Neuroimmunology, 2005, 163, 185-189.	1.1	78
77	Prolonged lesional expression of RhoA and RhoB following spinal cord injury. Journal of Comparative Neurology, 2005, 487, 166-175.	0.9	57
78	SekundÃre Immundefizienz nach ZNS-Verletzung: Charakteristika, Pathophysiologie und klinische Bedeutung. E-Neuroforum, 2005, 11, 5-13.	0.2	1
79	Spinal cord injury induction of lesional expression of profibrotic and angiogenic connective tissue growth factor confined to reactive astrocytes, invading fibroblasts and endothelial cells. Journal of Neurosurgery: Spine, 2005, 2, 319-326.	0.9	40
80	Injury-related dynamic myelin/oligodendrocyte axon-outgrowth inhibition in the central nervous system. Lancet, The, 2005, 365, 2055-2057.	6.3	19
81	Injury reactive myelin/oligodendrocyte-derived axon growth inhibition in the adult mammalian central nervous system. Brain Research Reviews, 2005, 49, 295-299.	9.1	12
82	Lesional Expression of RhoA and RhoB following Traumatic Brain Injury in Humans. Journal of Neurotrauma, 2004, 21, 697-706.	1.7	59
83	From Cell Death to Neuronal Regeneration: Building a New Brain after Traumatic Brain Injury. Journal of Neuropathology and Experimental Neurology, 2004, 63, 180-181.	0.9	3
84	Lesional RhoA+ cell numbers are suppressed by anti-inflammatory, cyclooxygenase-inhibiting treatment following subacute spinal cord injury. Glia, 2004, 47, 377-386.	2.5	31
85	Novel Neuroscience M.D.-Ph.D. Programs in Germany: A Chance for Neurosurgical Research?. Neurosurgery, 2004, 55, 1232-1233.	0.6	0
86	Lesional expression of a proinflammatory and antiangiogenic cytokine EMAP II confined to endothelium and microglia/macrophages during secondary damage following experimental traumatic brain injury. Journal of Neuroimmunology, 2003, 135, 1-9.	1.1	34
87	COX-3 the enzyme and the concept: steps towards highly specialized pathways and precision therapeutics?. Prostaglandins Leukotrienes and Essential Fatty Acids, 2003, 69, 339-343.	1.0	46
88	COX-3: just another COX or the solitary elusive target of paracetamol?. Lancet, The, 2003, 361, 981-982.	6.3	99
89	The Rho/ROCK pathway mediates neurite growth-inhibitory activity associated with the chondroitin sulfate proteoglycans of the CNS glial scar. Molecular and Cellular Neurosciences, 2003, 22, 319-330.	1.0	362
90	Spinal Cord Injury Induces Lesional Expression of the Proinflammatory and Antiangiogenic Cytokine EMAP II. Journal of Neurotrauma, 2003, 20, 1007-1015.	1.7	22

#	ARTICLE	IF	CITATIONS
91	COX-2 a virtual pain target in humans?. FASEB Journal, 2003, 17, 2174-2175.	0.2	59
92	Effect of Focal Cerebral Infarctions on Lesional RhoA and RhoB Expression. Archives of Neurology, 2003, 60, 1245-9.	4.9	35
93	Cyclooxygenases and Central Nervous System Inflammation. Archives of Neurology, 2003, 60, 630.	4.9	35
94	Persistent accumulation of cyclooxygenase-1 expressing microglial cells and macrophages and transient upregulation by endothelium in human brain injury. Journal of Neurosurgery, 2002, 96, 892-899.	0.9	81
95	Infiltrating CD14+ monocytes and expression of CD14 by activated parenchymal microglia/macrophages contribute to the pool of CD14+ cells in ischemic brain lesions. Journal of Neuroimmunology, 2002, 126, 107-115.	1.1	78
96	CD14 expression by activated parenchymal microglia/macrophages and infiltrating monocytes following human traumatic brain injury. Acta Neuropathologica, 2002, 103, 541-549.	3.9	127
97	AIF-1 expression defines a proliferating and alert microglial/macrophage phenotype following spinal cord injury in rats. Journal of Neuroimmunology, 2001, 119, 214-222.	1.1	83
98	Spinal infection with intraspinal abscess or empyema and acute myelopathy: comparative analysis of diagnostics, therapy, complications and outcome in primary care. European Journal of Trauma and Emergency Surgery, 0, , .	0.8	2